Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-828 vs D064+D701 in Healthy Adults
NCT05540912Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan and Levamlodipine in hypertension (HTN) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Sep 2022; status: completed.
02
Drugs
telmisartanLevamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05540912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540912.